ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag digital pcr evolution genetics genomics

Layered visual representation of multiomics
Integrate and Innovate with NGS and Multiomics
The Scientist and Illumina | May 4, 2023 | 6 min read
Researchers across disciplines combine layers of discovery obtained with accessible NGS-based multiomics approaches.
Top 10 Innovations 2021
2021 Top 10 Innovations
The Scientist | Dec 1, 2021 | 10+ min read
The COVID-19 pandemic is still with us. Biomedical innovation has rallied to address that pressing concern while continuing to tackle broader research challenges.
Genomics-Informed Pathology
Dennis P. Wall and Peter J. Tonellato | Jan 1, 2013 | 4 min read
Twenty-first century lab reports will include test results read by a new breed of pathologist.
Creative Emulsification
Sabrina Richards | Nov 1, 2012 | 8 min read
Enhancing data collection from emulsion PCR reactions: three case studies
A Flood in Genomics
Brendan Maher | Nov 25, 2001 | 9 min read
Nine months have passed since draft sequences of the human genome were first published.1,2 One human gestation period later, the genome, as deciphered by the International Human Genome Sequencing Consortium, still screams toward its projected Spring 2003 finish date. "The trajectory we're on for meeting that goal is precisely on target," assures Francis Collins, director, National Human Genome Research Institute (NHGRI) and spokesperson for the largest public biological science project in histor
Prospecting for Gold in Genome Gulch
Amy Adams | Apr 14, 2002 | 9 min read
The human genome is much like the American West of the 1850s: Everyone wants a piece of the pie. Similar to gold prospectors of 150 years ago, biotech and pharmaceutical companies, and even universities, are frantically searching for the nuggets of gold that will help them find the mother lode—a gene whose function is sufficiently marketable to make all of the preliminary research worthwhile. Companies that do strike gold get to introduce new classes of drugs to the market. Others hope to
Beyond Sanger: Toward the $1,000 Genome
Aileen Constans | Jun 29, 2003 | 10 min read
Courtesy of Solexa Total Genotyping Without a doubt, the quarter-century-old Sanger sequencing method performed like a champ during the Human Genome Project. But with the capacity to read only a few hundred bases per reaction, it is far too slow and expensive for routine use in clinical settings. Reaping the rewards of the genomics era will clearly require faster and cheaper alternatives. Some companies estimate that within the next five years, technical advances could drop the cost of seque
Deviations From The Norm: Systems For Mutation Detection Reveal Hidden Potentials
Kailash Gupta | Jul 18, 1999 | 10+ min read
Date: July 19, 1999Mutation Detection Systems and Methods Affymetrix's p53 chip Researchers leading the Human Genome Project (HGP) originally envisioned completion of the entire genome sequence (approximately 3 billion base pairs) by the year 2005. Recently the arena of human genome sequencing has seen a lot of heat generated by the entry of both commercial entrepreneurs and public consortia. Celera, a company formed by highly skilled and competent commercial organizations (TIGR and Perkin-Elm
2020 Top 10 Innovations
The Scientist | Dec 1, 2020 | 10+ min read
From a rapid molecular test for COVID-19 to tools that can characterize the antibodies produced in the plasma of patients recovering from the disease, this year’s winners reflect the research community’s shared focus in a challenging year.
Alternative Splicing Goes Mainstream
Sam Jaffe | Dec 14, 2003 | 10 min read
In eukaryotic genetics, the one-gene/one-protein concept has, for the most part, breathed its last. Researchers have rallied behind mechanisms such as alternative splicing, which may allow a lowly 30,000-gene genome to produce the dizzying variety of proteins that some believe is necessary to produce beings as complex as humans. Alternative splicing--the post-transcriptional editing process that can result in various mRNAs--was previously seen as an interesting but relatively uncommon sidesh

Run a Search

ADVERTISEMENT